Will larger biotech and pharma companies be seeking pipeline-enhancing, early-stage opportunities for long-term growth, or late-stage product opportunities? Will they seek to partner or look to acquire assets? A panel of experts will encourage life science company executives and their teams to think more strategically about their partnering approach in view of current market dynamics by offering cutting-edge perspectives on recent partnering trends, outlining the marketplace for biotech deals and pinpointing key drivers for making deals with pharma and larger biotech companies in the next year.



Objectives:

Forecast what partnering opportunities will be most attractive to large pharmaceutical companies in the next year, and why.

Offer a critique of recent dealmaking trends.

Provide a framework for structuring and executing successful strategic alliances in the next few years.